Table III.
Univariate and multivariate Cox proportional hazard regression analyses for disease-free survival.
| Univariate analysis | Multivariate analysis | |||||
|---|---|---|---|---|---|---|
|
|
|
|||||
| Factors | HR | 95% CI | P-value | HR | 95% CI | P-value |
| Age | ||||||
| (≥70 vs. <70 years) | 2.10 | 0.59-7.43 | 0.25 | |||
| Gender | ||||||
| (Male vs. Female) | 0.31 | 0.04-2.53 | 0.28 | |||
| Tumor location | ||||||
| (Upper/Middle vs. Lower) | 1.45 | 0.37-5.77 | 0.59 | |||
| Tumor size | ||||||
| (≥50 mm vs. <50 mm) | 0.64 | 0.16-2.56 | 0.53 | |||
| Differentiation | ||||||
| (Well/Moderate vs. Poor/Others) | 1.13 | 0.28-4.41 | 0.88 | |||
| cT | ||||||
| (T4 vs. <T3) | 2.61 | 0.73-9.40 | 0.14 | |||
| cN | ||||||
| (≥N2 vs. <N1) | 1.18 | 0.31-4.48 | 0.81 | |||
| Surgical procedure | ||||||
| (TG vs. DG) | 1.29 | 0.33-5.08 | 0.71 | |||
| NAC regimen | ||||||
| (DCS vs. SOX) | 3.27 | 0.78-13.73 | 0.09 | 2.37 | 0.67-8.98 | 0.45 |
| Histological grade | ||||||
| (0, 1 vs. 2, 3) | 1.71 | 0.32-9.00 | 0.53 | |||
| LCR | ||||||
| (Low vs. High) | 2.53 | 0.67-9.60 | 0.17 | |||
| NLR | ||||||
| (High vs. Low) | 4.23 | 0.57-31.42 | 0.06 | 6.45 | 1.23-45.34 | 0.04a |
| PNI | ||||||
| (Low vs. High) | 1.90 | 0.45-8.07 | 0.39 | |||
| PT response | ||||||
| (Non-res vs. Res) | 2.35 | 0.62-8.85 | 0.21 | |||
| LN response | ||||||
| (Non-res vs. Res) | 7.79 | 1.16-63.51 | 0.02a | 7.44 | 1.45-56.78 | 0.01a |
a
P<0.05. CI, confidence interval; DCS, docetaxel + cisplatin + S-1; DG, distal gastrectomy; HR, hazard ratio; LCR, lymphocyte-C-reactive protein ratio; LN, lymph node; NAC, neoadjuvant chemotherapy; NLR, neutrophil-lymphocyte ratio; Non-res, nonresponse; PNI, prognostic nutritional index; PT, primary tumor site; Res, response; SOX, S-1 + oxaliplatin; TG, total gastrectomy.